Giltertinib and ONO-7475 are AXL/FLT3 dual kinase inhibitors that have been reported to inhibit adaptive resistance to early EGFR-TKI treatment in EGFR-mutant NSCLC (Mori et al., 2017; Okura et al., 2020). Here, AXL is linked to non-small cell lung carcinoma.